Even therecent published trials of dipeptidyl peptidase-4 inhibitors in patients with type 2diabetes and high cardiovascular risk did not show a reduction in cardiovascularevents [11–13], but there was a concernregarding heart failure incidence in two of the trials [12,90]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.